BioSpace News Archive

Oryzon Genomics, S.A., a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announced that Executive Directors of the company will present at several reputed international conferences in December.

Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through a subsidiary, to evaluate the combination of Seattle Genetics’ and Astellas’ antibody-drug conjugate (ADC) enfortumab vedotin and Merck’s anti-PD-1 therapy, KEYTRUDA®

Health Sciences Acquisitions Corporation (“HSAC,” NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments, LP, announced today that it has set a record date and a meeting date for the special meeting of its stockholders to, among other things, consider and vote on a proposal to approve the transactions contemplated by the previously announced share exchange agreement pursuant to which HSAC will acquire 100% of the issued and outstanding shares in Immunovant Sciences Ltd

Recently Released Combined Reporting Package and Risk Assessment Tools Driving Momentum

BioLife Solutions, Inc. announced several executive appointments to further support the integration of Astero Bio, SAVSU Technologies, and Custom Biogenic Systems, three companies acquired during 2019.

Research Foundation to Cure AIDS (RFTCA) announced plans to nucleate its AIDS cure incubator at Northwell Health in the former AIDS ward of St. Vincent’s Hospital in New York City, where thousands suffered and died of AIDS.

Sustained improvements in multiple health outcomes following twelve monthly buprenorphine extended-release injections in patients with opioid use disorder

Compass Therapeutics, a biotechnology company focused on drugging the human immune synapse to treat human diseases, will present at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 in New York, NY.

PellePharm, Inc., a BridgeBio Pharma, Inc. company, announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in patients with Gorlin Syndrome.

Closing conditions waived - Amended & Restated Partnership Agreement is now closed